University Of Michigan Develops New Urine Test That Detects High-Grade Prostate Cancer As An Alternative To Biopsies

Cancer News: Prostate cancer is a significant health concern for men worldwide, with varying degrees of aggressiveness and potential for harm. The University of Michigan Rogel Cancer Center has spearheaded a groundbreaking development in prostate cancer detection with their new urine-based test, MyProstateScore2.0 (MPS2) that is covered in this Cancer News report. This test is designed to identify high-grade prostate cancer, particularly Gleason 3+4=7 or Grade Group 2 (GG2) and higher, allowing for a more accurate assessment of cancer aggressiveness and the necessity of immediate treatment.


New Urine Test That Detects High-Grade Prostate Cancer As An Alternative To Biopsies

The Need for Precision in Prostate Cancer Detection
Traditional methods of prostate cancer detection, such as the prostate-specific antigen (PSA) test, often struggle to differentiate between slow-growing cancers that may not require immediate treatment and aggressive cancers that demand urgent attention. This dilemma has led to numerous unnecessary biopsies and treatments, causing undue stress and potential side effects for patients.
 
Dr John T. Wei, co-senior study author and David A. Bloom Professor of Urology at Michigan Medicine explained, "Our conventional test is deficient in accurately identifying individuals with significant cancer. Two decades ago, our focus was on detecting any form of cancer. However, our understanding has evolved, recognizing that slow-growing cancers may not require immediate treatment. This shift has transformed our approach, emphasizing the importance of identifying only clinically significant cancer.”
 
Evolution of MyProstateScore: From MPS to MPS2
The journey towards MPS2 began nearly a decade ago with the development of the original MyProstateScore (MPS) test by the same team at the University of Michigan. MPS incorporated PSA levels, the TMPRSS2::ERG gene fusion, and the PCA3 marker. While a step forward, MPS still faced challenges in accurately detecting high-grade or clinically significant prostate cancer.
 
The Science Behind MPS2: Unveiling 18 Key Biomarkers
To enhance the precision of prostate cancer detection, researchers utilized RNA sequencing to identify over 58,000 genes associated with prostate cancer.
 
Through rigorous analysis, they pinpointed 54 candidate markers that were uniquely overexpressed in higher-grade cancers. This extensive process culminated in the selection of 18 key biomarkers that consistently correlated with high-grade disease.
 
The identified biomarkers included genes associated with aggressive tumor growth, metastatic potential, and resistance to conventional therapies. These genes provided insights into the molecular pathways driving high-grade prostate cancer, allowing for a more targeted and effective diagnostic approach.
 
Validation and Clinical Utility of MPS2
The validation process fo r MPS2 involved testing against urine samples from over 800 patients, including those with elevated PSA levels who underwent prostate biopsies. The results were promising, with MPS2 demonstrating a nearly 100% accuracy in ruling out low-grade cancers (GG1) and significantly reducing unnecessary biopsies by up to 41%.
 
The clinical utility of MPS2 extends beyond its diagnostic accuracy. It also serves as a valuable tool for risk stratification, guiding clinicians in determining the appropriate course of action for patients with suspected prostate cancer. By reliably identifying high-grade cancers, MPS2 empowers healthcare providers to make informed decisions regarding treatment strategies, thus optimizing patient care and outcomes.
 
Clinical Implications and Patient Benefits
One of the most significant advantages of MPS2 is its ability to guide clinical decisions, particularly in patients with a history of negative biopsies or elevated PSA levels. The test's high negative predictive value ensures that patients with a negative MPS2 result can confidently forego unnecessary biopsies, reducing both physical discomfort and emotional distress.
 
Moreover, MPS2 offers a personalized approach to prostate cancer management. By accurately stratifying patients based on their risk of high-grade cancer, the test enables tailored treatment plans that prioritize aggressive intervention for those who need it most while sparing others from unnecessary procedures and potential side effects.
 
Comparative Analysis and Superiority of MPS2
Compared to existing biomarker tests endorsed by guidelines, MPS2 stands out for its superior diagnostic accuracy, especially in detecting high-grade prostate cancer. Its negative predictive values ranging from 95% to 99% for GG2 or greater cancers and 99% for GG3 or greater cancers underscore its reliability and clinical relevance.
 
Co-senior author Professor Dr Arul M. Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S. P. Hicks Endowed Professor of Pathology and professor of urology at Michigan Medicine commented, "If you're negative on this test, it's almost certain that you don't have aggressive prostate cancer. Moreover, MPS2 was more effective at helping patients avoid unnecessary biopsies. While 11% of unnecessary biopsies were avoided with PSA testing alone, MPS2 testing would avoid up to 41% of unnecessary biopsies. Four of 10 men who would have a negative biopsy will have a low risk MPS2 result and can confidently skip a biopsy. If a man has had a biopsy before, the test works even better.”
 
In contrast, traditional biomarker tests often lack the specificity and sensitivity required to accurately differentiate between low-grade and high-grade prostate cancer. This limitation can lead to overdiagnosis of indolent cancers and unnecessary biopsies, highlighting the critical need for more advanced diagnostic tools like MPS2.
 
Integration into Clinical Practice and Future Outlook
MPS2's availability through LynxDx, a University of Michigan spin-off company, paves the way for its integration into routine clinical practice. Its potential to reduce unnecessary biopsies, mitigate harms associated with overdiagnosis, and improve patient outcomes marks a significant milestone in prostate cancer management.
 
The adoption of MPS2 into clinical practice represents a shift towards personalized medicine in prostate cancer care. By leveraging cutting-edge technology and molecular insights, MPS2 empowers healthcare providers to deliver tailored and effective treatments that address the individual needs of each patient.
 
Conclusion: Transforming Prostate Cancer Care
The University of Michigan's MPS2 test represents a paradigm shift in prostate cancer detection, offering a precise and non-invasive alternative to traditional biopsy-based approaches. By leveraging cutting-edge molecular techniques and a robust validation process, MPS2 empowers clinicians to make informed decisions, sparing patients from unnecessary procedures and ensuring timely intervention for high-risk cases. As this innovative test becomes more widely adopted, it holds the promise of revolutionizing prostate cancer care, ultimately improving outcomes and quality of life for men globally.
 
The study findings were published in the peer reviewed journal: JAMA Oncology.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2817657
 
For the latest Cancer News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/herbs-and-phytochemicals-alpha-santalol-from-sandalwood-can-prevent-development-of-prostate-cancer
 
https://www.thailandmedical.news/news/medical-news-uk-study-finds-that-carnosine-could-be-used-to-treat-prostate-cancer
 
https://www.thailandmedical.news/news/medical-news-singapore-doctors-warn-that-acute-covid-19-infections-can-cause-elevated-psa-levels,-complicating-prostate-cancer-diagnosis